Contribute Try STAT+ Today

When hundreds of scientists from around the world finally pieced together a draft of the first human genome in 2003, perhaps the biggest surprise was just how little of it was devoted to the business of producing proteins. About 98% of the genes in our chromosomes appeared not to do anything, earning the unflattering nickname “junk DNA.” But with better tools developed over the last 20 years, scientists began to discover that all that junk actually produces a diverse menagerie of RNA species transcribed and set loose to drift around the cell.

Figuring out exactly what each one does is the mission of an increasing number of researchers, including a team at MD Anderson Cancer Center in Texas. Years ago, they set out to determine the functions of one RNA species in particular — big ones, larger than 200 bases, known as long noncoding RNAs, or lncRNAs. Now, they’ve linked one of these RNA molecules to a discovery they say could aid in the development of new treatments for one of the most common genetic disorders, phenylketonuria.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment